XTAE
ICHO
Market cap46mUSD
Dec 21, Last price
110.90ILS
Name
DNA Group TR Ltd
Chart & Performance
P/E
6.18
P/S
446.36
EPS
0.18
Div Yield, %
—
Shrs. gr., 5y
37.59%
Rev. gr., 5y
%
Revenues
306k
0.00%
Net income
22m
P
CFO
2m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dna Group (T.R.) Ltd, along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of proprietary ultrasound technologies. These advanced systems are utilized to evaluate bone strength and density, as well as to detect and monitor calcium leakage associated with osteoporosis in both adult and pediatric patients. The company's offerings are employed by trained physicians, nurses, and operators within hospitals, clinics, pharmacies, and various other healthcare environments across Israel, North America, East Asia, and international markets. Beyond its core ultrasound business, the group is also involved in the creation of oral medications. Established in 2004 and based in Tel Aviv-Yafo, Israel, the company was formerly known as D.N.A Biomedical Solutions Ltd. before adopting its current name in November 2022.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||